If BRAF V600E mutations are documented in NSCLC, why are such agents as vemurafenib and dabrafenib considered by the NCCN to have

If BRAF V600E mutations are documented in NSCLC, why are such agents as vemurafenib and dabrafenib considered by the NCCN to have "targeted activity" against this tumor profile?

If BRAF V600E mutations are documented in NSCLC, why are such agents as vemurafenib and dabrafenib considered by the NCCN to have “targeted activity” against this tumor profile?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Paul Mitchell, BHB, MBChB, FRACP, MD

Paul Mitchell, BHB, MBChB, FRACP, MD

Associate Professor
Senior Specialist
Austin Health Cancer Services
Director, North Eastern Metropolitan Integrated Cancer Services (NEMICS)
Melbourne, Australia